Improving Memory in Patients With Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

1999-09-30

Study Completion Date

2002-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People with multiple sclerosis (MS) suffer from cognitive and other brain problems. This study will examine the effectiveness of the drug donepezil and of sugar water for enhancing memory in individuals with MS. Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)

NCT02301247

Multiple Sclerosis, Progressive Cognition - Other Memory Impairment

COMPLETED NA

Neural Stem Cell Transplantation in Multiple Sclerosis Patients

NCT03269071

Progressive Multiple Sclerosis

COMPLETED PHASE1

Consolidation & Interference in Multiple Sclerosis

NCT02081508

Multiple Sclerosis

COMPLETED NA

Testing the Efficacy of Self-Generation Treatment Protocol

NCT02032589

Multiple Sclerosis

UNKNOWN NA

A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis

NCT02647502

Relapsing Remitting Multiple Sclerosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cognitive dysfunction is one of the leading causes of disability in people with MS. Memory involving specific words (verbal memory) is particularly affected in individuals with MS. Attempts to rehabilitate cognitive dysfunction in MS have had only limited success.

This study will determine the efficacy of donepezil therapy and glucose administration for enhancing verbal memory functioning in individuals with MS. The study will also measure secondary outcomes assessing other areas of cognitive dysfunction (i.e., nonverbal memory, conceptual thinking, processing speed) which may improve with intervention.

Forty participants with MS will be randomly assigned to receive either donepezil or placebo for 24 weeks. Participants will complete memory and cognitive tests at the beginning and end of the 24 week period.

Twenty participants with MS will be randomly assigned to drink a beverage sweetened with either glucose or saccharin (placebo). Participants will then complete memory and other cognitive tests. Two weeks later, participants will drink a beverage sweetened with the alternative sweetener and again complete the memory and cognitive tests.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

donepezil

Intervention Type DRUG

glucose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MS as defined by the Poser criteria
* Expanded Disability Status Scale (EDSS) score of 0 to 6.5
* Stable neurologic function for at least 30 days prior to study entry
* Agree to continue all current medications for study duration
* Rey Auditory Verbal Learning Test score in low normal range or below
* Mini-mental status exam score of 26 or higher
* Montgomery-Asberg Depression Scale scaled score of 14 or lower
* Fluent in English

Exclusion Criteria

* Use of anticholinergic or benzodiazepine medication
* Change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry
* Current alcohol or substance abuse
* History of neurological or major medical problem that has a known effect on cognitive functioning
* History of noncompliance
* Visual or upper extremity impairment which precludes ability to participate in cognitive assessment

Minimum Eligible Age

18 Years

Maximum Eligible Age

56 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No